Active substance
Cilostazol
- SFDA 2
- US FDA 17
- US price lines 2
- NHS prices 2
- Safety 2
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| FANCATA 100MG TABLET | 100 mg | Tablet · Oral use | 60 Blister | SAR 67.40 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| FANCATA 50MG TABLET | 50 mg | Tablet · Oral use | 60 Blister | SAR 52.95 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| CILOSTAZOL | 50MG; 100MG | tablet · oral | AUROBINDO PHARMA USA | Prescription | 23 Nov 2004 |
| CILOSTAZOL | 100MG; 50MG | tablet · oral | EPIC PHARMA LLC | Prescription | 23 Nov 2004 |
| CILOSTAZOL | 50MG; 100MG | tablet · oral | TEVA | Prescription | 24 Nov 2004 |
| CILOSTAZOL | 100MG | tablet · oral | ACTAVIS ELIZABETH | Prescription | 26 Nov 2004 |
| CILOSTAZOL | 50MG; 100MG | tablet · oral | APOTEX | Prescription | 10 Dec 2004 |
| CILOSTAZOL | 100MG; 50MG | tablet · oral | SLATE RUN PHARMA | Prescription | 29 Mar 2006 |
| CILOSTAZOL | 50MG | tablet · oral | CHARTWELL RX | Prescription | 24 Sep 2012 |
| CILOSTAZOL | 100MG; 50MG | tablet · oral | CHARTWELL RX | Prescription | 24 Sep 2012 |
| PLETAL | 50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet · oral | OTSUKA | Discontinued | 15 Jan 1999 |
| CILOSTAZOL | 100MG | tablet · oral | CHARTWELL RX | Discontinued | 23 Nov 2004 |
| CILOSTAZOL | 100MG | tablet · oral | ACTAVIS ELIZABETH | Discontinued | 26 Nov 2004 |
| CILOSTAZOL | 100MG | tablet · oral | IVAX SUB TEVA PHARMS | Discontinued | 1 Mar 2005 |
| CILOSTAZOL | 50MG; 100MG | tablet · oral | HIKMA PHARMS | Discontinued | 17 May 2005 |
| CILOSTAZOL | 50MG | tablet · oral | CHARTWELL RX | Discontinued | 8 Nov 2005 |
| CILOSTAZOL | 100MG; 50MG | tablet · oral | RISING | Discontinued | 20 Apr 2006 |
| CILOSTAZOL | 50MG; 100MG | tablet · oral | PLIVA HRVATSKA DOO | Discontinued | 29 Oct 2007 |
| CILOSTAZOL | 50MG; 100MG | tablet · oral | SANKALP LIFECARE | Discontinued | 28 Sep 2009 |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | CILOSTAZOL 100 MG TABLET | $0.13176 | per EA | 23 Sep 2026 |
| US NADAC | CILOSTAZOL 50 MG TABLET | $0.13039 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Cilostazol 100mg tablets | £56.57 | 56 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Cilostazol 50mg tablets | £35.31 | 56 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 17 May 2017 PLETAL — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions - MHRA 11 Dec 2014 Cilostazol (Pletal): risks of cardiovascular and bleeding events
Indication restricted to second-line treatment and contraindicated with some cardiovascular conditions and medicines Furthermore, cilostazol is now contraindicated in patients with any of the following: Unstable angina, recent myocardial infarction or coronary intervention (within 6 months) a history of severe tachyarrhythmia those receiving two or more other antiplatelet or anticoagulant treatments For patients starting cilostazol, prescribers should assess benefit after 3 months of treatment, and should stop treatment if patients have not made clinically relevant improvements in walking distance. All patients who are currently receiving long-term treatment should be reassessed at a routine appointment, in light of the new advice.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.